Abstract
Neuromuscular blockade is often necessary to ensure patient safety and optimize response to mechanical ventilation in critically ill children.[1,2] Cisatracurium, introduced in the United States in 1995, has become one of the most widely used neuromuscular blocking agents in the pediatric patient population. Its shorter duration of action, unique organ-independent elimination, and low incidence of adverse effects have made cisatracurium an appealing alternative to older agents such as pancuronium and vecuronium.[1,2]
Pediatr Pharm. 2013;19(9) © 2013 Children's Medical Center, University of Virginia
